Neurocrine Biosciences

Yahoo Finance • 13 days ago

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 mil... Full story

Yahoo Finance • 26 days ago

Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday

We recently compiled a list of the 10 Companies Echo Friday's Market Pessimism.In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks. Ten companies were hit hard on... Full story

Yahoo Finance • 28 days ago

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug

Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza. Continue Reading View Comments... Full story

Yahoo Finance • last month

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and commercialize... Full story

Yahoo Finance • 5 months ago

Exploring Three High Growth Tech Stocks in the United States

Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance... Full story

Yahoo Finance • 5 months ago

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specificall... Full story

Yahoo Finance • 6 months ago

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors Wednesday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) topline data for its Phase 2 clinical study of NBI-1117568... Full story

Yahoo Finance • 7 months ago

Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)

On August 15, 2024, Director William Rastetter executed a sale of 14,250 shares of Neurocrine Biosciences Inc (NASDAQ:NBIX) as reported in the SEC Filing. Following this transaction, the insider now owns 37,491 shares of the company. The s... Full story

Yahoo Finance • 10 months ago

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statistically Significant Reduction in MADRS Sco... Full story

Yahoo Finance • 11 months ago

Top 12 Stocks in George Soros’ Stock Portfolio

In this article, we discuss the top 12 stocks in George Soros’ stock portfolio. To skip the details on Soros’ life, investment philosophy, and his fund’s latest bets, go directly to the Top 5 Stocks in George Soros' Stock Portfolio. Billi... Full story

Yahoo Finance • last year

Director Richard Pops Sells 15,000 Shares of Neurocrine Biosciences Inc

Richard Pops, a director at Neurocrine Biosciences Inc (NASDAQ:NBIX), executed a sale of 15,000 shares in the company on February 20, 2024, according to a recent SEC Filing. Neurocrine Biosciences Inc is a biopharmaceutical company focused... Full story

Yahoo Finance • last year

Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks

In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks. The... Full story

Yahoo Finance • last year

Neurocrine Biosciences Full Year 2023 Earnings: EPS Beats Expectations

Neurocrine Biosciences (NASDAQ:NBIX) Full Year 2023 Results Key Financial Results Revenue: US$1.89b (up 27% from FY 2022). Net income: US$249.7m (up 62% from FY 2022). Profit margin: 13% (up from 10% in FY 2022). EPS: US$2.56 (up from US... Full story

Yahoo Finance • last year

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript February 7, 2024 Neurocrine Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). O... Full story

Yahoo Finance • last year

Neurocrine Biosciences Inc CFO Matt Abernethy Sells Company Shares

Neurocrine Biosciences Inc (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases and disorders, has reported an insider sell transaction. According to a recent SEC Filin... Full story

Yahoo Finance • last year

Neurocrine Biosciences Inc's Chief Legal Officer Sells Shares

Darin Lippoldt, the Chief Legal Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), sold 10,000 shares of the company on January 22, 2024, according to a recent SEC Filing. The transaction was executed at a price of $139.86 per share, res... Full story

Yahoo Finance • last year

Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 2, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Tuesday January 9, 2024 in San Francisco. Kevin Gorman, Chie... Full story

Yahoo Finance • last year

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story

Yahoo Finance • last year

Neurocrine Biosciences' (NASDAQ:NBIX) five-year earnings growth trails the 12% YoY shareholder returns

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd like to see the share price move up more than the market average. Unfortunately for shareholders, while the Neurocrine... Full story

Yahoo Finance • last year

Insider Sell: Chief Medical Officer Eiry Roberts Sells Shares of Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NASDAQ:NBIX), a prominent player in the biopharmaceutical industry, has recently witnessed a significant insider sell by its Chief Medical Officer, Eiry Roberts. On December 8, 2023, Eiry Roberts sold a substant... Full story